Alvotech (ALVO) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free ALVO Stock Alerts $13.29 -0.08 (-0.60%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 10:19 AM | finance.yahoo.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 13 at 8:00 AM | globenewswire.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 13 at 8:00 AM | globenewswire.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 2, 2024 | globenewswire.comAlvotech Announces Participation at BofA Securities Healthcare Conference 2024May 2, 2024 | globenewswire.comAlvotech Announces Participation at BofA Securities Healthcare Conference 2024April 30, 2024 | finance.yahoo.comAlvotech (ALVO)April 30, 2024 | businesswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 30, 2024 | globenewswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 30, 2024 | globenewswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 24, 2024 | globenewswire.comAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)April 24, 2024 | globenewswire.comAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)April 21, 2024 | uk.investing.comAlvotech expands US reach with biosimilar to HumiraApril 19, 2024 | globenewswire.comAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)April 19, 2024 | globenewswire.comAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)April 17, 2024 | markets.businessinsider.comAlvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic ArthritisApril 16, 2024 | marketwatch.comAlvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis TreatmentApril 16, 2024 | msn.comFDA approves Alvotech biosimilar of J&J top-selling drug StelaraApril 16, 2024 | finance.yahoo.comAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)April 3, 2024 | globenewswire.comAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024April 3, 2024 | globenewswire.comAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024March 23, 2024 | seekingalpha.comAlvotech (ALVO) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | globenewswire.comAlvotech Announces Increase in Number of Own SharesMarch 22, 2024 | globenewswire.comAlvotech Announces Increase in Number of Own SharesMarch 22, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before LongMarch 22, 2024 | uk.finance.yahoo.comQ4 2023 Alvotech SA Earnings CallMarch 20, 2024 | investorplace.comALVO Stock Earnings: Alvotech Reported Results for Q4 2023March 20, 2024 | globenewswire.comAlvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateMarch 20, 2024 | globenewswire.comAlvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateMarch 16, 2024 | finance.yahoo.comTEVA Mar 2024 10.000 callMarch 6, 2024 | finance.yahoo.comTEVA Mar 2024 15.500 putMarch 5, 2024 | globenewswire.comAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ETMarch 5, 2024 | globenewswire.comAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ETMarch 2, 2024 | uk.investing.comAlvotech appoints new interim Chief Quality OfficerMarch 2, 2024 | finance.yahoo.comTEVA Mar 2024 14.500 putFebruary 29, 2024 | globenewswire.comAlvotech Appoints Interim Chief Quality OfficerFebruary 29, 2024 | globenewswire.comAlvotech Appoints Interim Chief Quality OfficerFebruary 27, 2024 | finance.yahoo.comTEVA Jun 2024 14.000 putFebruary 26, 2024 | seekingalpha.comTeva And Alvotech: Simlandi Approval Opens New Generic Market OpportunitiesFebruary 26, 2024 | msn.comFDA approves Alvotech-Teva’s SIMLANDI jab for multiple conditionsFebruary 26, 2024 | finance.yahoo.comHumira biosimilar from Alvotech, Teva wins FDA approval on third attemptFebruary 26, 2024 | investorplace.comTEVA Stock Pops 4% as Teva Receives FDA ApprovalFebruary 26, 2024 | marketwatch.comAlvotech Shares Rise Premarket After Humira Biosimilar ApprovalFebruary 26, 2024 | globenewswire.comAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per ShareFebruary 26, 2024 | globenewswire.comAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per ShareFebruary 25, 2024 | finance.yahoo.comTEVA Apr 2024 14.000 callFebruary 25, 2024 | finance.yahoo.comTEVA Apr 2024 12.500 putFebruary 25, 2024 | msn.comAlvotech (ALVO) Price Target Increased by 10.45% to 12.58February 24, 2024 | markets.businessinsider.comAlvotech And Teva Announce U.S. Approval Of SIMLANDI InjectionFebruary 24, 2024 | finance.yahoo.comTEVA Mar 2024 11.500 putFebruary 24, 2024 | finance.yahoo.comTEVA Mar 2024 12.500 call Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. ALVO Media Mentions By Week ALVO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼0.000.58▲Average Medical News Sentiment ALVO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼32▲ALVO Articles Average Week Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FATE News Today LXEO News Today ITOS News Today REPL News Today TCRX News Today ADPT News Today TRML News Today OCGN News Today TSHA News Today EDIT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ALVO) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
